BeammWave has resolved a directed issue of ~SEK20m to institutional investor MetaSpace Fund and a co...
Redeye comments on Transtema’s Q1 report. While the adjusted EBITA was somewhat softer than expected...
Q1 showed sales decreasing 8% y/y, leading to a miss of 8% vs SEB expectations.
Redeye provides its initial take on Moberg Pharma’s Q1 report, which saw sales slightly exceed expec...
Yesterday, QBY reported Q1'26 results that came in below our already cautious estimates.
* NOI 5% y-o-y, +3.4% vs ABGSCe, +1.3% vs cons. * Value changes of +0.
Alzecures fas 1b-studie med ACD856 på fyrtio friska frivilliga deltagare är slutförd enligt plan.
Q1 looks solid, with a 9% PFPM beat versus consensus, positive value changes (0.
Redeye updates on W5 Solutions after Q1-results which were better-than-expected.
Redeye returns with a revised outlook following GomSpace's Q1 report that demonstrated financial pro...
Redeye presents its preview for Paxman’s Q1 2026 report, due on May 21.
Redeye retains its positive view of q.beyond even though Q1 came in short of our expectations.
For Q1, we forecast 8% sales growth y/y (+17% FX-adjjusted) and EBIT of SEK -6m (-8m last year).
Redeye provides a brief comment on Oncopeptides' decision to submit a type II variation to expand th...
Earlier today, Waystream announced a five-year framework agreement with GlobalConnect, one of Northe...
Redeye is positive about the large SEK23m order from ClearPoint Neuro, as we believe it provides muc...
Q1 preliminary sales grew 8% yoy to € 22.3m, marking the first quarter with top-line growth since Q1...
Mendus’s Q126 results reflect the execution of its expanded clinical strategy for vididencel, with t...
(Link updated) Last week, Roche announced the acquisition of PathAI for up to $ 1.
BeammWave’s Q1 keeps the commercialisation story alive, but the share is running ahead of hard evide...